Controlled Delivery of Nitric Oxide for Cancer Therapy

(E-pub Ahead of Print)

Author(s): Houman Alimoradi, Khaled Greish*, Allan B Gamble, Gregory I Giles.

Journal Name: Pharmaceutical Nanotechnology

Become EABM
Become Reviewer

Abstract:

Nitric oxide (NO) is a short-lived, endogenously produced signaling molecule which plays multiple roles in mammalian physiology. Underproduction of NO is associated with several pathological processes; hence a broad range of NO donors have emerged as potential therapeutics for cardiovascular and respiratory disorders, wound healing, the immune response to infection, and cancer. However, short half-lives, chemical reactivity, rapid systemic clearance, and cytotoxicity have hindered the clinical development of most low molecule weight NO donors. Hence, for controlled NO delivery, there has been extensive effort to design novel NO-releasing biomaterials for tumor targeting. This review covers the effects of NO in cancer biology, NO releasing moieties which can be used for NO delivery, and the current advances in the design of NO releasing biomaterial focusing on their applications for tumor therapy.

Keywords: Nitric Oxide, Controlled Delivery, Nitric Oxide Donors, Nitric Oxide Releasing Biomaterials, Nanoparticles

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/2211738507666190429111306

Article Metrics

PDF: 4